

## Debates and Didactics in Hematology and Oncology

Sea Island, Georgia  
August 7-10, 2014

### Course Directors

#### **Sagar Lonial, MD**

Professor and Vice Chair for Clinical Affairs  
Department of Hematology & Medical Oncology  
Winship Cancer Institute  
Emory University

#### **Fadlo Khuri, MD, FACP**

Deputy Director, Winship Cancer Institute;  
Professor and Chair of Hematology and Medical  
Oncology, Pharmacology and Otolaryngology;  
Roberto C. Goizueta Distinguished Chair  
in Cancer Research  
Emory University

### Guest Faculty

**Kenneth Anderson, MD**, Program Director and Chief, Division of Hematologic Neoplasias; Kraft Family Professor of Medicine, Harvard Medical School; Dana-Farber Cancer Institute

**James Armitage, MD**, Professor, Department of Internal Medicine; Joe Shapiro Distinguished Chair of Oncology, University of Nebraska Medical Center

**Michael Atkins, MD**, Professor of Medicine, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center

**George Fisher, MD, PhD**, Professor of Medicine, Stanford University School of Medicine

**Hagop Kantarjian, MD**, Chairman and Professor, Department of Leukemia, University of Texas, M. D. Anderson Cancer Center

**Susan O'Brien, MD**, Professor of Medicine, Department of Leukemia, University of Texas, M. D. Anderson Cancer Center

### Moderators

**F. Robert Krywicki, MD, FACP**, Phoebe Putney Medical Center, Albany, Georgia (Thursday, August 7)

**Grant C. Lewis, MD**, Summit Cancer Care, Savannah, Georgia (Friday, August 8)

**Andrew Pippas, MD**, John B. Amos Cancer Center, Columbus, Georgia (Saturday, August 9)

### Winship Cancer Institute Faculty

**Martha Arellano, MD**, Associate Professor of Hematology and Medical Oncology

**Jonathan Beitler, MD, MBA, FACR**, Professor of Radiation Oncology, Otolaryngology, Hematology and Oncology; Georgia Research Alliance Cancer Scientist

**Kenneth Cardona, MD**, Assistant Professor of Surgery

**Bradley Carthon, MD, PhD**, Assistant Professor of Hematology and Medical Oncology, Genitourinary Medical Oncology

**Jonathon Cohen, MD, MS**, Assistant Professor of Hematology and Medical Oncology

**Ian Crocker, MD, FACR, FRCP(C)**, Professor of Radiation Oncology

**Walter J. Curran, Jr, MD**, Executive Director of Winship Cancer Institute; Lawrence W. Davis Professor and Chair of Radiation Oncology; Group Chairman, NRG Oncology; Georgia Research Alliance Eminent Scholar and Chair in Cancer Research

**Keith Delman, MD**, Associate Professor/Carlos Professor of Surgery

**Bassel El-Rayes, MD**, Associate Professor of Medical Oncology, Associate Director for Clinical Research and Director of Gastrointestinal Oncology Program

**Costas G. Hadjipanayis, MD, PhD**, Associate Professor of Neurosurgery, Chief of Neurosurgery Service

**Leonard T. Heffner, Jr, MD**, Professor of Hematology and Medical Oncology

**Ira Horowitz, MD, SM, FACOG, FACS**, Professor and Chair of Gynecology and Obstetrics, Chief Medical Officer of Emory University Hospital

**Anand Jillella, MD**, Professor of Hematology and Medical Oncology, Associate Director for Community Affairs and Outreach

**Christine Kempton, MD, MSc**, Assistant Professor of Pediatrics and Hematology and Medical Oncology

**H. Jean Khoury, MD**, R. Randall Rollins Professor of Hematology and Medical Oncology; Director, Division of Hematology

**Omer Kucuk, MD**, Professor of Hematology and Medical Oncology

**Ragini Kudchadkar, MD**, Assistant Professor of Hematology and Medical Oncology

**Amelia Langston, MD**, Professor of Hematology and Medical Oncology; Director and Section Chief, Bone Marrow Transplant Program

**David Lawson, MD**, Professor of Hematology and Medical Oncology; Co-Chair, Emory Melanoma and Pigmented Lesion Center

**Mary Jo Lechowicz, MD**, Associate Professor of Hematology and Medical Oncology; Advisor and Leader, Osler Society, Emory Undergraduate Medical Education

**Shishir Maithel, MD**, Assistant Professor of Surgical Oncology

**Viraj Master, MD, PhD, FACS**, Associate Professor of Urology

**Morgan McLemore, MD**, Assistant Professor of Hematology and Medical Oncology

**Ruth O'Regan, MD**, Professor of Hematology and Medical Oncology and Vice Chair for Educational Affairs; Louisa and Rand Glenn Family Chair in Breast Cancer Research; Chief of Service, Georgia Cancer Center for Excellence, Grady Health System

**Taofeek Owonikoko, MD, PhD**, Assistant Professor of Hematology and Medical Oncology

**Rathi Pillai, MD**, Assistant Professor of Hematology and Medical Oncology

**Suresh Ramalingam, MD**, Professor of Hematology and Medical Oncology

**Charles Staley, MD**, Holland M. Ware Professor of Surgery; Professor and Chief, Division of Surgical Oncology; Associate Director for Clinical Affairs

**Mylin Torres, MD**, Assistant Professor of Radiation Oncology

**Alfredo Voloschin, MD**, Assistant Professor of Hematology and Medical Oncology

**Edmund Waller, MD, PhD, FACP**, Professor of Hematology and Medical Oncology; Director, Division of Stem Cell Transplantation and Immunotherapy

**Elliott Winton, MD**, Professor of Hematology and Medical Oncology

**Amelia Zelnak, MD**, Assistant Professor of Hematology and Medical Oncology

## **LEARNING OBJECTIVES**

After successful completion of this educational activity, participants should be able to:

- Evaluate the risks and benefits of emerging therapies and novel treatment strategies for patients with solid tumors and hematologic malignancies, as well as the practical utility of these approaches based on recent clinical data
- Apply best practices regarding the treatment of patients with cancer, including integration of novel therapeutic approaches and individualization of care
- Appropriately integrate multimodality therapy and multidisciplinary care to improve the management of patients with cancer
- Identify appropriate clinical trials in which to enroll patients with cancer

**AGENDA**

**Thursday, August 7, 2014**

**Genitourinary/Non-Hodgkin Lymphoma/Other**

7.30 AM	Debate 1: Upfront nephrectomy vs upfront systemic therapy in metastatic renal cell carcinoma (RCC) patients <i>Pro upfront nephrectomy:</i> Viraj Master, MD, PhD, FACS <i>Pro upfront systemic therapy:</i> Bradley Carthon, MD, PhD
7.55 AM	Lecture 1: Immune-based therapeutic approaches in genitourinary (GU) malignancies Michael Atkins, MD
8.20 AM	Lecture 2: Prostate cancer 2014 and beyond Omer Kucuk, MD

**Genitourinary Malignancies**

8.45 AM	Debate 2: High-dose chemotherapy and transplant as standard therapy for patients failing first-line chemotherapy in metastatic germ cell tumors <i>Pro:</i> Edmund Waller, MD, PhD, FACP <i>Con:</i> Bradley Carthon, MD, PhD
---------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Germ Cell**

9.10 AM	Lecture 3: State of the art treatment for relapsed mantle cell lymphoma Jonathon Cohen, MD, MS
9.35 AM	BREAK
10.05 AM	Lecture 4: NHL in clinically difficult situations James Armitage, MD
10.30 AM	Lecture 5: Acute promyelocytic leukemia – Current management with emphasis on prevention of induction mortality Anand Jillella, MD
10.55 AM	Lecture 6: New targets and treatments for follicular NHL Jonathon Cohen, MD, MS
11.20 AM	Lecture 7: Improving outcomes for HPV-related head and neck cancer Jonathan Beitler, MD, MBA, FACR
11.45 AM	Debate 3: Radiation as consolidation in the treatment of newly diagnosed CNS lymphoma versus after failure of chemotherapy <i>Pro Newly Diagnosed:</i> Ian Crocker, MD, FACR, FRCP(C) <i>Pro After Chemotherapy Failure:</i> Alfredo Voloschin, MD

**Lymphoma/Head and Neck/Leukemia**

12.10 PM Lunch

12.40 PM Challenging cases: Genitourinary malignancies and lymphoma

1.40 PM Adjourn

Friday, August 8, 2014

Breast/Multiple Myeloma/Leukemia

7.30 AM	Debate 1: Treatment of older patients with AML – Intensive or non-intensive therapy <i>Pro Intensive:</i> Martha Arellano, MD <i>Pro Non-Intensive:</i> Amelia Langston, MD	Leukemia
7.55 AM	Lecture 1: Contemporary and future approaches in the management of CML Hagop Kantarjian, MD	
8.20 AM	Lecture 2: New determinants and approaches for MPD Elliott Winton, MD	
8.45 AM	Debate 2: ALL allogeneic transplant in CR1 or CR2? <i>Pro CR1:</i> Amelia Langston, MD <i>Pro CR2:</i> H. Jean Khoury, MD	
9.10 AM	Lecture 3: Updates in the management of CLL Susan O'Brien, MD	

9.35 AM BREAK

10.05 AM	Lecture 4: Recent advances in therapy for HER2-positive breast cancer Ruth O'Regan, MD	Breast Cancer
10.30 AM	Lecture 5: What do we really know about intraoperative radiotherapy? Mylin Torres, MD	
10.55 AM	Debate 3: Pathologic complete response is a valid surrogate for long-term outcome for early-stage breast cancer <i>Pro:</i> Amelia Zelnak, MD <i>Con:</i> Ruth O'Regan, MD	
11.20 AM	Debate 4: Removal of the breast primary in patients with metastatic breast cancer <i>Pro:</i> Mylin Torres, MD <i>Con:</i> Amelia Zelnak, MD	

11.45 AM Lunch

12.15 PM	Lecture 6: Induction for newly-diagnosed multiple myeloma: Implementation of a long-term plan Sagar Lonial, MD	Multiple Myeloma
12.40 PM	Lecture 7: Management of relapsed/refractory multiple myeloma Kenneth Anderson, MD	

1.05 PM Lecture 8: New anti-coagulants – When and why should I use them?  
Christine Kempton, MD, MSc

1.30 PM Challenging cases: Breast cancer and myeloma (or leukemia)

2.30 PM Adjourn

Saturday, August 9, 2014

Lung/Melanoma/Other

7.30 AM	Lecture 1: Immune checkpoint inhibitors and other new agents in NSCLC Rathi Pillai, MD	Lung Cancer
7.55 AM	Lecture 2: Managing resistance to TKI therapy in lung cancer Fadlo Khuri, MD, FACP	
8.20 AM	Lecture 3: Multidisciplinary approaches to NSCLC Suresh Ramalingam, MD	
8.45 AM	Debate 1: Adjuvant TKI therapy for driver mutations in early-stage disease after systemic chemotherapy <i>Pro:</i> Suresh Ramalingam, MD <i>Con:</i> Fadlo Khuri, MD, FACP	
9.10 AM	Lecture 4: New treatments in the management of thyroid cancer Taofeek Owonikoko, MD, PhD	Thyroid
9.35 AM	BREAK	
10.05 AM	Lecture 5: Treatment of T-cell lymphomas Mary Jo Lechowicz, MD	T-cell
10.30 AM	Lecture 6: Combination targeted therapy for melanoma: Ready for primetime? Ragini Kudchadkar, MD	Melanoma
10.55 AM	Debate 2: High-dose IL-2: Is there still a role? <i>Pro:</i> David Lawson, MD <i>Con:</i> Ragini Kudchadkar, MD	
11.20 AM	Lecture 7: Management of immunotherapy-related adverse events Ragini Kudchadkar, MD	
11.45 AM	Debate 3: Is there a role for surgical resection of stage 4 melanoma any longer? <i>Pro:</i> Keith Delman, MD <i>Con:</i> David Lawson, MD	
12.10 PM	Lunch	
12.40 PM	Lecture 8: Sarcoma update and new approaches Kenneth Cardona, MD	Sarc
1.05 PM	Lecture 9: Optimizing first-line treatment of advanced ovarian cancer Ira Horowitz, MD, SM, FACOG, FACS	Ov Ca
1.30 PM	Challenging cases: Lung cancer and melanoma	
2.30 PM	Adjourn	

Sunday, August 10, 2014

Gastrointestinal/Hematology/Other

7.30 AM	Lecture 1: Update on rectal cancer Charles Staley, MD	Gastrointestinal Malignancies
7.45 AM	Lecture 2: Optimizing sequencing for colorectal cancer –What is best and when? Bassel El-Rayes, MD	
8.00 AM	Lecture 3: Liver-directed therapy for colorectal liver metastases Shishir Maithel, MD	
8.15 AM	Challenging cases in pancreatic cancer – Tumor board cases	
8.45 AM	Lecture 4: New treatments for neuroendocrine cancers George Fisher, MD, PhD	NET
9.10 AM	Lecture 5: New treatment approaches for glioblastoma Costas G. Hadjipanayis, MD, PhD	GBM
9.35 AM	Lecture 6: Where do we go next in the multidisciplinary management of glioblastoma? Walter Curran, Jr, MD	
10.00 AM	Lecture 7: Advances in the management of MDS Martha Arellano, MD	MDS
10.25 AM	Lecture 8: Hemoglobinopathies – Workup and diagnosis Morgan McLemore, MD	Heme
10.50 AM	Lecture 9: Waldenström’s macroglobulinemia: New drugs and new treatments Leonard T. Heffner, Jr, MD	Myeloma
11.15 AM	Concluding Remarks	
11.30 AM	Adjourn	